TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

VTAMA

TAPINAROF Aryl Hydrocarbon Receptor Agonists
Immunology Approved 2022-05-23
2
Indications
--
Phase 3 Trials
3
Years on Market

Details

Status
Prescription
First Approved
2022-05-23
Routes
TOPICAL
Dosage Forms
CREAM

Companies

Active Ingredient: TAPINAROF

VTAMA Approval History

Loading approval history...

What VTAMA Treats

2 indications

VTAMA is approved for 2 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Plaque Psoriasis
  • Atopic Dermatitis
Source: FDA Label

Drugs Similar to VTAMA

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ZORYVE
ROFLUMILAST
2 shared
ARCUTIS
Shared indications:
Plaque PsoriasisAtopic Dermatitis
ADBRY
TRALOKINUMAB
1 shared
LEO PHARMA AS
Shared indications:
Atopic Dermatitis
AVAGE
TAZAROTENE
1 shared
ALMIRALL
Shared indications:
Plaque Psoriasis
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
BETAMETHASONE ACETATE
1 shared
Hikma
Shared indications:
Atopic Dermatitis
BIMZELX
BIMEKIZUMAB-BKZX
1 shared
UCB INC
Shared indications:
Plaque Psoriasis
BRYHALI
HALOBETASOL PROPIONATE
1 shared
BAUSCH
Shared indications:
Plaque Psoriasis
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
BETAMETHASONE DIPROPIONATE
1 shared
SUN PHARMA CANADA
Shared indications:
Plaque Psoriasis
CELESTONE SOLUSPAN
BETAMETHASONE ACETATE
1 shared
Merck
Shared indications:
Atopic Dermatitis
CIBINQO
ABROCITINIB
1 shared
Pfizer
Shared indications:
Atopic Dermatitis
CIMZIA
CERTOLIZUMAB PEGOL
1 shared
UCB INC
Shared indications:
Plaque Psoriasis
CLOBEX
CLOBETASOL PROPIONATE
1 shared
GALDERMA LABS
Shared indications:
Plaque Psoriasis
CYLTEZO
ADALIMUMAB-ADBM
1 shared
Boehringer Ingelheim
Shared indications:
Plaque Psoriasis
DEPO-MEDROL
METHYLPREDNISOLONE ACETATE
1 shared
Pfizer
Shared indications:
Atopic Dermatitis
DEXAMETHASONE
DEXAMETHASONE
1 shared
ALVOGEN
Shared indications:
Atopic Dermatitis
DEXAMETHASONE INTENSOL
DEXAMETHASONE
1 shared
Hikma
Shared indications:
Atopic Dermatitis
DEXYCU KIT
DEXAMETHASONE
1 shared
EYEPOINT PHARMS
Shared indications:
Atopic Dermatitis
DUOBRII
HALOBETASOL PROPIONATE
1 shared
BAUSCH
Shared indications:
Plaque Psoriasis
DUPIXENT
DUPILUMAB
1 shared
Regeneron
Shared indications:
Atopic Dermatitis
EBGLYSS
LEBRIKIZUMAB-LBKZ
1 shared
Eli Lilly
Shared indications:
Atopic Dermatitis
ELIDEL
PIMECROLIMUS
1 shared
BAUSCH
Shared indications:
Atopic Dermatitis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

VTAMA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

VTAMA cream, 1% is an aryl hydrocarbon receptor agonist indicated for: the topical treatment of plaque psoriasis in adults. the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older. 1.1 Plaque Psoriasis VTAMA ® cream is indicated for the topical treatment of plaque psoriasis in adults. 1.2 Atopic Dermatitis VTAMA cream is indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.

VTAMA Patents & Exclusivity

Latest Patent: Nov 2039
Exclusivity: Dec 2027

Patents (13 active)

US11590088 Expires Nov 13, 2039
US11497718 Expires Nov 13, 2039
US11938099 Expires Nov 13, 2039
US10647649 Expires Nov 13, 2038
US11597692 Expires Nov 13, 2038
US10426743 Expires May 19, 2036
US11612573 Expires May 19, 2036
US11617724 Expires May 19, 2036
US10195160 Expires May 19, 2036
US11622945 Expires May 19, 2036
+ 3 more patents

Exclusivity

I-956 Until Dec 2027
NCE Until May 2027
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.